386 related articles for article (PubMed ID: 28906392)
1. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.
Wei J; Zhang W; Feng L; Gao W
Medicine (Baltimore); 2017 Sep; 96(37):e8034. PubMed ID: 28906392
[TBL] [Abstract][Full Text] [Related]
2. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Shao F; Li Y; Zhao Y
Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
[TBL] [Abstract][Full Text] [Related]
3. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
4. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
6. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
7. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.
Gallos ID; Yap J; Rajkhowa M; Luesley DM; Coomarasamy A; Gupta JK
Am J Obstet Gynecol; 2012 Oct; 207(4):266.e1-12. PubMed ID: 23021687
[TBL] [Abstract][Full Text] [Related]
8. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
9. Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta-analysis.
Zhao S; Zhang J; Yan Y; Tian L; Chen L; Zheng X; Sun Y; Tian W; Xue F; Wang Y
Acta Obstet Gynecol Scand; 2024 Feb; ():. PubMed ID: 38382917
[TBL] [Abstract][Full Text] [Related]
10. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
11. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
12. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
13. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
14. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
15. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.
Zhou S; Xu Z; Yang B; Guan J; Shan W; Shi Y; Chen X
J Gynecol Oncol; 2021 Jul; 32(4):e57. PubMed ID: 34085795
[TBL] [Abstract][Full Text] [Related]
16. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
[TBL] [Abstract][Full Text] [Related]
17. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.
Herrera Cappelletti E; Humann J; Torrejón R; Gambadauro P
Hum Reprod Update; 2022 Feb; 28(2):282-295. PubMed ID: 34935045
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
Xi Y; Liu G; Liu D; Jiang J; Gong R
Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
[TBL] [Abstract][Full Text] [Related]
19. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
20. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
He YJ; Wang YQ; Tang HR; He M; Rao Y; Zhou R; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):21-28. PubMed ID: 32074769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
